Rajesh Kumar
Stock Analyst at HSBC
(2.62)
# 2,208
Out of 4,920 analysts
22
Total ratings
60%
Success rate
13.2%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Hold | n/a | $47.22 | - | 1 | Jul 31, 2025 | |
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,150 → $700 | $765.95 | -8.61% | 2 | Apr 28, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $260 → $160 | $183.93 | -13.01% | 1 | Apr 25, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $33.32 | +26.05% | 1 | Apr 25, 2025 | |
| ABBV AbbVie | Upgrades: Buy | $185 | $198.55 | -6.82% | 3 | Jun 5, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $466.42 | +43.65% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $199.04 | +40.68% | 2 | Apr 17, 2024 | |
| UNH UnitedHealth Group | Upgrades: Hold | $460 | $251.00 | +83.27% | 2 | Apr 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Buy | $13 | $15.71 | -17.25% | 1 | Dec 18, 2023 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Hold | $55 → $53 | $45.85 | +15.59% | 2 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $27.47 | +253.11% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $111.07 | +11.64% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.75 | +102.02% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $80.79 | +52.25% | 1 | Jul 14, 2023 |
Novo Nordisk
Jul 31, 2025
Downgrades: Hold
Price Target: n/a
Current: $47.22
Upside: -
Eli Lilly and Company
Apr 28, 2025
Downgrades: Reduce
Price Target: $1,150 → $700
Current: $765.95
Upside: -8.61%
IQVIA Holdings
Apr 25, 2025
Downgrades: Hold
Price Target: $260 → $160
Current: $183.93
Upside: -13.01%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $33.32
Upside: +26.05%
AbbVie
Jun 5, 2024
Upgrades: Buy
Price Target: $185
Current: $198.55
Upside: -6.82%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $466.42
Upside: +43.65%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $199.04
Upside: +40.68%
UnitedHealth Group
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $251.00
Upside: +83.27%
Teva Pharmaceutical Industries
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $15.71
Upside: -17.25%
Bristol-Myers Squibb Company
Oct 27, 2023
Upgrades: Hold
Price Target: $55 → $53
Current: $45.85
Upside: +15.59%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $27.47
Upside: +253.11%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $111.07
Upside: +11.64%
Jul 14, 2023
Initiates: Buy
Price Target: $50
Current: $24.75
Upside: +102.02%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $80.79
Upside: +52.25%